Back to Archived Journals » Virus Adaptation and Treatment » Volume 4

New agents for the treatment of hepatitis C virus – focus on telaprevir

Authors Thompson A, Patel K

Received 21 May 2012

Accepted for publication 6 July 2012

Published 1 November 2012 Volume 2012:4 Pages 75—84


Checked for plagiarism Yes

Review by Single anonymous peer review

Peer reviewer comments 2

AJ Thompson,1–3 K Patel3

1Department of Gastroenterology, St Vincent's Hospital, University of Melbourne, 2Victorian Infectious Diseases Reference Laboratory, North Melbourne, Victoria, Australia; 3Duke Clinical Research Institute and Department of Gastroenterology, Duke University Medical Center, Durham, NC, USA

Abstract: Antiviral therapy for hepatitis C virus (HCV) is rapidly evolving with the advent of direct-acting antiviral agents. Telaprevir is a first-generation linear ketoamide inhibitor of HCV NS3 protease. Approved in 2011 as standard-of-care for the treatment of patients chronically infected with HCV genotype 1, telaprevir represents a major therapeutic advance. Used in combination with PEGylated interferon-alfa and ribavirin, telaprevir-based regimens cured > 75% of treatment-naïve patients in the Phase III registration studies. Telaprevir is also effective for patients who have previously failed interferon-based therapy. Telaprevir presents a number of new challenges for clinicians, including a more demanding dosing schedule, telaprevir-specific adverse events, potential for drug–drug interactions, and selection of drug-resistant HCV variants.

Keywords: telaprevir, HCV, NS3, protease inhibitor, resistance

Creative Commons License This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at and incorporate the Creative Commons Attribution - Non Commercial (unported, v3.0) License. By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms.

Download Article [PDF]